GoKawiilReview maps current drugs and pipeline candidates for treating MASH
A new review synthesizes the evolving treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH), the liver disease formerly called NASH, drawing on updated epidemiological data, revised diagnostic terminology, and studies on liver fibrosis assessment. It outlines existing approaches alongside emerging therapies aimed at addressing the disease's metabolic, cardiovascular and cancer-related complications.